Biomark Diagnostics Inc. (DB: 20B)
Health Care · Biotechnology · CA
€0.33
+2.52% today · +90.6% 1Y
Biomark Diagnostics Inc. (DB: 20B) operates in the Biotechnology industry within the Health Care sector. The company is valued at $39.07M.
Over the last twelve months the share price has gained 90.6%, trading between 0.15 and 0.42.
Tweenvest scores Biomark Diagnostics Inc. across four factors: quality 23/100, value 60/100. Its strongest factor is value.
20B price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $39.07M
- Revenue (TTM)
- $19.58K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- -0.38
- 52-week high
- €0.42
- 52-week low
- €0.15
- Avg volume (3M)
- —
- Shares outstanding
- 106.48M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Novacyt S.A.ENXTPA: ALNOV | $39.88M | €0.47 | -4.37% |
| Cantargia AB (publ)OM: CANTA | $39.59M | Skr1.33 | -5.61% |
| J2KBIO Co., Ltd.KOSDAQ: A420570 | $39.29M | ₩9,050.00 | -1.84% |
| Amplia Therapeutics LimitedASX: ATX | $39.24M | AU$0.11 | -8.33% |
| NeoCore Technology Co., Ltd.TPEX: 4131 | $38.54M | NT$30.80 | -3.75% |
| CEL-SCI CorporationNYSEAM: CVM | $37.46M | $1.95 | -8.45% |
| Metagenomi Therapeutics, Inc.NasdaqGS: MGX | $37.20M | $0.99 | +0.86% |
| Sprint Bioscience AB (publ)OM: SPRINT | $37.11M | Skr3.64 | +3.12% |
Figures last refreshed Oct 4, 2026.